Our recent published results found that stable CAD patients with elevated plasma LIGHT [23] and DcR3 [24] have a high risk of cardiovascular events after percutaneous coronary intervention (PCI) treatment. The gene discussed is TNFRSF6B; the disease is coronary artery disorder.